BioSpace News Archive

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture units

Through a series of studies, researchers at The Feinstein Institutes for Medical Research have shown that mitochondria transplantation (MTx), delivering new mitochondria to critical tissues, can improve survival and neurological outcomes after cardiac arrest.

KaiNexus (www.kainexus.com), the leading Lean and Continuous Improvement software company, announced a partnership today with the Center for Lean Engagement and Research (CLEAR), a research center at the UC Berkeley School of Public Health.

Alcresta Therapeutics, Inc. today announced publication of preclinical data from the company’s development device ALC-078 in a porcine short bowel syndrome (SBS) model.

Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the market open.

Intera Oncology ® Inc. has reintroduced Hepatic Artery Infusion (HAI) therapy to the market after its discontinuation in 2018 by the prior manufacturer dismayed patients and physicians.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland.

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational palovarotene as a potential treatment for fibrodysplasia ossificans progressiva (FOP), is 16 August 2023.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2022 on Thursday, March 23, 2023.

Pfizer Inc. announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness.